Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, ...

William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today.Don't Miss our Black Friday ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals said they have entered a licensing and collaboration agreement worth more than $1 billion.

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Sarepta Therapeutics今日宣布与Arrowhead ...

Arrowhead Pharmaceuticals (ARWR) stock surges 21% in premarket after $825M licensing deal with Sarepta (SRPT) for rare ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

马萨诸塞州剑桥 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT)与Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)签订了一项全球许可协议,获得了一系列针对肌肉、中枢神经系统 ...

周二，摩根士丹利重申了对Sarepta Therapeutics的积极立场，维持其增持评级和200.00美元的目标价。这家金融公司的分析是在Sarepta宣布一项重大合作协议后进行的，预计该协议将增强其研发能力。

From COVID-19 vaccines to rare disease treatments, RNA has become key to tackling many of biotech’s tough obstacles. Stoke ...